MX2013007007A - Vacunas a base de peptidos de la proteina c5a de complemento. - Google Patents
Vacunas a base de peptidos de la proteina c5a de complemento.Info
- Publication number
- MX2013007007A MX2013007007A MX2013007007A MX2013007007A MX2013007007A MX 2013007007 A MX2013007007 A MX 2013007007A MX 2013007007 A MX2013007007 A MX 2013007007A MX 2013007007 A MX2013007007 A MX 2013007007A MX 2013007007 A MX2013007007 A MX 2013007007A
- Authority
- MX
- Mexico
- Prior art keywords
- seq
- amino acid
- peptides
- peptide fragment
- complement protein
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 102000000989 Complement System Proteins Human genes 0.000 title 1
- 108010069112 Complement System Proteins Proteins 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108010033276 Peptide Fragments Proteins 0.000 abstract 3
- 102000007079 Peptide Fragments Human genes 0.000 abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 3
- 102000014914 Carrier Proteins Human genes 0.000 abstract 1
- 108010078791 Carrier Proteins Proteins 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
Abstract
La presente invención se relaciona con una vacuna que comprende al menos un péptido que consiste de la secuencia de aminoácidos LRANISHKDMQLGR (SEC ID NO. 1) o un fragmento del péptido de este (SEC ID NO. 2-13) acoplado o fusionado con una proteína portadora que comprende al menos un epítopo de células T, en donde el fragmento de péptido comprende al menos 7 residuos de aminoácidos y la secuencia de aminoácidos KDMQLGR (SEC ID NO. 7) o KDMQLGR (SEC ID NO. 23) bajo la provisión que el fragmento de aminoácidos no consiste de las secuencias de aminoácidos HKDMQLGR (SEC ID NO. 16) y HKDMQLG (SEC ID NO. 22).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10196232A EP2468295A1 (en) | 2010-12-21 | 2010-12-21 | Vaccines based on peptides of the complement protein C5a |
PCT/EP2011/073599 WO2012085090A1 (en) | 2010-12-21 | 2011-12-21 | Vaccines based on peptides of the complement protein c5a |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2013007007A true MX2013007007A (es) | 2013-07-29 |
Family
ID=43929080
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013007007A MX2013007007A (es) | 2010-12-21 | 2011-12-21 | Vacunas a base de peptidos de la proteina c5a de complemento. |
Country Status (16)
Country | Link |
---|---|
US (1) | US9457078B2 (es) |
EP (2) | EP2468295A1 (es) |
JP (1) | JP6016803B2 (es) |
KR (1) | KR20140053816A (es) |
CN (1) | CN103269711B (es) |
BR (1) | BR112013011285A2 (es) |
CA (1) | CA2822266A1 (es) |
DK (1) | DK2654778T3 (es) |
ES (1) | ES2718632T3 (es) |
IL (1) | IL225671A0 (es) |
MX (1) | MX2013007007A (es) |
NZ (1) | NZ608889A (es) |
PL (1) | PL2654778T3 (es) |
RU (1) | RU2013133875A (es) |
SG (1) | SG189842A1 (es) |
WO (1) | WO2012085090A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2954687A1 (en) * | 2014-07-10 | 2016-01-14 | Affiris Ag | Substances and methods for the use in prevention and/or treatment in huntington's disease |
CN116731149B (zh) * | 2023-06-07 | 2024-02-27 | 华中农业大学 | 草鱼补体活化分子碳末端肽C5a-CP及应用 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4686100A (en) | 1985-04-02 | 1987-08-11 | The Board Of Trustees Of The Leland Stanford Junior University | Method for the treatment of adult respiratory distress syndrome |
EP0245993B1 (en) | 1986-04-28 | 1993-05-26 | Cetus Oncology Corporation | Monoclonal antibodies against c5a and des-arg74-c5a, their production and use |
JPH04503073A (ja) * | 1989-01-31 | 1992-06-04 | アボツト・ラボラトリーズ | アナフィラトキシン受容体リガンド |
US5807824A (en) | 1993-12-06 | 1998-09-15 | Ciba-Geigy Corporation | C5A receptor antagonists having substantially no agonist activity |
US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
JPH08109200A (ja) | 1994-08-19 | 1996-04-30 | Takeda Chem Ind Ltd | 抗C5aレセプター抗体、その製造法および用途 |
US5696230A (en) | 1994-08-31 | 1997-12-09 | The Board Of Regents Of The University Of Nebraska | High-affinity response-selective C-terminal analogs of C5a anaphylatoxin |
WO1996039503A1 (en) * | 1995-06-05 | 1996-12-12 | Novartis Ag | C5a RECEPTOR ANTAGONISTS HAVING SUBSTANTIALLY NO AGONIST ACTIVITY AND METHODS FOR PREPARATION |
AUPO755097A0 (en) | 1997-06-25 | 1997-07-17 | University Of Queensland, The | Receptor agonist and antagonist |
US6673346B1 (en) * | 1999-08-31 | 2004-01-06 | The Regents Of The University Of Michigan | Compositions and methods for the treatment of sepsis |
CA2457461C (en) | 2001-08-17 | 2013-12-24 | Tanox, Inc. | Complement pathway inhibitors binding to c5 and c5a without preventing the formation of c5b |
EP1878441B1 (en) | 2001-08-17 | 2018-01-24 | Genentech, Inc. | Complement pathway inhibitors binding to C5 and C5a without preventing the formation of C5b |
AU2003202297C1 (en) | 2002-01-25 | 2006-05-18 | G2 Therapies Ltd | Anti-C5aR antibodies and uses thereof |
ITMI20021527A1 (it) * | 2002-07-11 | 2004-01-12 | Consiglio Nazionale Ricerche | Anticorpi anti componente c5 del complemento e loro uso |
NZ538384A (en) | 2002-09-06 | 2009-04-30 | Alexion Pharma Inc | Treatment for asthma using a compound which binds to or otherwise blocks the generation and/or activity of one or more complement components reptors, such as, C5a receptors |
DE60326264D1 (de) | 2002-12-02 | 2009-04-02 | Resistentia Pharmaceuticals Ab | Verfahren und materialien zur behandlung von entzündungen unter verwendung eines polypeptides das einen eigenen-c5 aminosaüresegment und einen nicht-eigenen aminosaüresegment enthält |
WO2005079363A2 (en) * | 2004-02-12 | 2005-09-01 | Archemix Corporation | Aptamer therapeutics useful in the treatment of complement-related disorders |
JP2006151866A (ja) | 2004-11-29 | 2006-06-15 | Canon Inc | フェナントロリン化合物及び発光素子 |
ATE497405T1 (de) | 2005-03-11 | 2011-02-15 | Potentia Pharmaceuticals Inc | Zusammensetzungen mit modulatoren des g-protein- gekoppelten rezeptors zur behandlung von makuladegeneration |
MX2007015781A (es) * | 2005-06-14 | 2008-02-15 | Cytos Biotechnology Ag | Conjugados antigenos y sus usos. |
WO2009015087A2 (en) * | 2007-07-20 | 2009-01-29 | Potentia Pharmaceuticals, Inc. | Compositions and methods for treatment of trauma |
RU2010138612A (ru) | 2008-02-20 | 2012-03-27 | Джи2 ИНФЛЕММЕЙШН ПТИ ЛТД (AU) | ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ C5аR |
NZ603226A (en) * | 2010-04-30 | 2015-02-27 | Alexion Pharma Inc | Anti-c5a antibodies and methods for using the antibodies |
-
2010
- 2010-12-21 EP EP10196232A patent/EP2468295A1/en not_active Withdrawn
-
2011
- 2011-12-21 CA CA2822266A patent/CA2822266A1/en not_active Abandoned
- 2011-12-21 US US13/879,740 patent/US9457078B2/en not_active Expired - Fee Related
- 2011-12-21 KR KR1020137013674A patent/KR20140053816A/ko not_active Application Discontinuation
- 2011-12-21 BR BR112013011285A patent/BR112013011285A2/pt not_active IP Right Cessation
- 2011-12-21 WO PCT/EP2011/073599 patent/WO2012085090A1/en active Application Filing
- 2011-12-21 CN CN201180061862.XA patent/CN103269711B/zh not_active Expired - Fee Related
- 2011-12-21 SG SG2013025804A patent/SG189842A1/en unknown
- 2011-12-21 EP EP11802093.2A patent/EP2654778B1/en not_active Not-in-force
- 2011-12-21 JP JP2013545364A patent/JP6016803B2/ja not_active Expired - Fee Related
- 2011-12-21 RU RU2013133875/10A patent/RU2013133875A/ru not_active Application Discontinuation
- 2011-12-21 DK DK11802093.2T patent/DK2654778T3/en active
- 2011-12-21 NZ NZ608889A patent/NZ608889A/en not_active IP Right Cessation
- 2011-12-21 ES ES11802093T patent/ES2718632T3/es active Active
- 2011-12-21 MX MX2013007007A patent/MX2013007007A/es not_active Application Discontinuation
- 2011-12-21 PL PL11802093T patent/PL2654778T3/pl unknown
-
2013
- 2013-04-10 IL IL225671A patent/IL225671A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
DK2654778T3 (en) | 2019-04-15 |
EP2654778B1 (en) | 2019-01-23 |
BR112013011285A2 (pt) | 2019-09-24 |
PL2654778T3 (pl) | 2019-09-30 |
AU2011347341A8 (en) | 2016-06-16 |
KR20140053816A (ko) | 2014-05-08 |
CN103269711B (zh) | 2016-06-08 |
CN103269711A (zh) | 2013-08-28 |
JP6016803B2 (ja) | 2016-10-26 |
JP2014501745A (ja) | 2014-01-23 |
AU2011347341A1 (en) | 2013-05-02 |
IL225671A0 (en) | 2013-06-27 |
ES2718632T3 (es) | 2019-07-03 |
SG189842A1 (en) | 2013-06-28 |
US9457078B2 (en) | 2016-10-04 |
NZ608889A (en) | 2014-05-30 |
US20130216565A1 (en) | 2013-08-22 |
EP2654778A1 (en) | 2013-10-30 |
RU2013133875A (ru) | 2015-01-27 |
AU2011347341B2 (en) | 2016-05-12 |
EP2468295A1 (en) | 2012-06-27 |
CA2822266A1 (en) | 2012-06-28 |
WO2012085090A1 (en) | 2012-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ598356A (en) | Antigenic tau peptides and uses thereof | |
NZ600732A (en) | Oxyntomodulin peptide analogue | |
CL2013003416A1 (es) | Secuencia de peptidos quiméricos que comprende dsspl o dasph composiciones , usos y metodo para mejorar metabolismo de glucosa. | |
UA110599C2 (uk) | Пептид для імунотерапії пухлин, включаючи нейрональні пухлини та пухлини мозку | |
RU2021134101A (ru) | Модифицированная j-цепь | |
MX343386B (es) | Proteinas de fusion portadoras de peptido como vacunas para alergia. | |
IN2012DN02993A (es) | ||
NZ600731A (en) | Oxyntomodulin peptide analogue | |
RU2016146198A (ru) | Терапевтические dll4-связывающие белки | |
MX2019015502A (es) | L-asparaginasa modificada. | |
CY1118856T1 (el) | Εμβολιο pcsk9 | |
MX2016002937A (es) | Vacuna oncologica. | |
NZ609916A (en) | Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof | |
NZ609216A (en) | Anticancer fusion protein | |
WO2012051498A3 (en) | Antibodies that bind amyloid oligomers | |
WO2016130628A8 (en) | Griffithsin mutants | |
MX2017010359A (es) | Cadena alfa del receptor de inmunoglobulina e (ige) de alta afinidad de fusion de fragmento cristalizable (fc). | |
NZ586074A (en) | LCLRP peptides, constructs and uses thereof | |
NZ609474A (en) | Fviii peptides for immune tolerance induction and immunodiagnostics | |
NZ598932A (en) | Identification of antigenic peptides from multiple myeloma cells | |
NZ724196A (en) | Uti fusion proteins | |
MX2009007261A (es) | Vacuna de peptido foxp3. | |
IN2014DN09963A (es) | ||
ES2572367T3 (es) | Péptidos con epítopos de la MELK y vacunas que los contienen | |
PH12018500468A1 (en) | Fusion protein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |